Steven Bird

1.8k total citations
28 papers, 944 citations indexed

About

Steven Bird is a scholar working on Physiology, Surgery and Pharmacology. According to data from OpenAlex, Steven Bird has authored 28 papers receiving a total of 944 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Physiology, 9 papers in Surgery and 7 papers in Pharmacology. Recurrent topics in Steven Bird's work include Asthma and respiratory diseases (7 papers), Respiratory and Cough-Related Research (6 papers) and Lipoproteins and Cardiovascular Health (6 papers). Steven Bird is often cited by papers focused on Asthma and respiratory diseases (7 papers), Respiratory and Cough-Related Research (6 papers) and Lipoproteins and Cardiovascular Health (6 papers). Steven Bird collaborates with scholars based in United States, Canada and United Kingdom. Steven Bird's co-authors include Jonathan M. Edelman, Carolyn M. Hustad, Andrew M. Tershakovec, Paul Chervinsky, Harold Bays, Scott Conard, Lawrence A. Leiter, Bruce Friedman, Joanne E. Tomassini and Joseph Rubino and has published in prestigious journals such as Journal of Clinical Oncology, PEDIATRICS and Spine.

In The Last Decade

Steven Bird

27 papers receiving 901 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Steven Bird United States 20 345 338 280 135 117 28 944
Eyal Leibovitz Israel 18 179 0.5× 270 0.8× 87 0.3× 124 0.9× 45 0.4× 73 1.0k
Carlos Alves Portugal 18 49 0.1× 168 0.5× 76 0.3× 109 0.8× 136 1.2× 54 1.2k
Florence N. Hutchison United States 21 127 0.4× 174 0.5× 144 0.5× 83 0.6× 52 0.4× 42 1.2k
Dong‐Soo Kim South Korea 21 50 0.1× 509 1.5× 176 0.6× 91 0.7× 84 0.7× 91 1.3k
Haralambos Milionis Greece 16 82 0.2× 309 0.9× 172 0.6× 227 1.7× 38 0.3× 29 1.0k
Ming‐Yow Hung Taiwan 17 69 0.2× 356 1.1× 76 0.3× 85 0.6× 78 0.7× 39 1.0k
Stanislav Šuškovič Slovenia 14 340 1.0× 32 0.1× 388 1.4× 59 0.4× 60 0.5× 25 863
P. J. Brombacher Netherlands 15 210 0.6× 161 0.5× 197 0.7× 109 0.8× 43 0.4× 57 910
Jetty A. Overbeek Netherlands 14 89 0.3× 115 0.3× 94 0.3× 94 0.7× 35 0.3× 57 716
C G Wathen United Kingdom 16 126 0.4× 140 0.4× 478 1.7× 115 0.9× 29 0.2× 56 1.2k

Countries citing papers authored by Steven Bird

Since Specialization
Citations

This map shows the geographic impact of Steven Bird's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven Bird with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven Bird more than expected).

Fields of papers citing papers by Steven Bird

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven Bird. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven Bird. The network helps show where Steven Bird may publish in the future.

Co-authorship network of co-authors of Steven Bird

This figure shows the co-authorship network connecting the top 25 collaborators of Steven Bird. A scholar is included among the top collaborators of Steven Bird based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven Bird. Steven Bird is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bird, Steven. (2024). Must NLP be Extractive?. 14915–14929.
2.
Bays, Harold, Scott Conard, Lawrence A. Leiter, et al.. (2010). Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?. Lipids in Health and Disease. 9(1). 136–136. 19 indexed citations
3.
Bays, Harold, Scott Conard, Lawrence A. Leiter, et al.. (2010). Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. International Journal of Cardiology. 153(2). 141–147. 9 indexed citations
4.
Gottlieb, Stephen S., Michael M. Givertz, Marco Metra, et al.. (2010). The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study. Journal of Cardiac Failure. 16(9). 714–719. 24 indexed citations
5.
Zieve, Franklin J., Nanette K. Wenger, Ori Ben‐Yehuda, et al.. (2009). Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study). The American Journal of Cardiology. 105(5). 656–663. 39 indexed citations
6.
Conard, Scott, Harold Bays, Lawrence A. Leiter, et al.. (2008). Efficacy and Safety of Ezetimibe Added on to Atorvastatin (20 mg) Versus Uptitration of Atorvastatin (to 40 mg) in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease††Conflicts of interest: Dr. Conard served as a consultant and advisor for Merck & Company and Merck/Schering-Plough. Dr. Bays received research grants from Amylin, San Diego, California, Amgen, Thousand Oaks, California, J&J, Langhorne, Pennsylvania, Aegerion, Bridgewater, New Jersey, Abbott, Chicago, Illinois, Arena Pharmaceuticals, San Diego, California, GlaxoSmithKline (Glaxo), London, UK, Hoffmann LaRoche, Nutley, New Jersey, Merck, Whitehouse Station, New Jersey, MSP, Kenilworth, New Jersey, Metabolex, San Jose, California, Schering-Plough, Kenilworth, New Jersey, Orexigen, San Diego, California, Reliant, Liberty Corner, New Jersey, Sciele, Atlanta, Georgia, Takeda, Osaka, Japan, TAP, Lake Forest, Illinois, and Vivus, Mountain View, California; received speakers' honoraria from Abbott, Daiichi Sankyo, Tokyo, Japan, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; received honoraria from Abbott, AstraZeneca, London, UK (Wilmington, Delaware, US Headquarters), Daiichi Sankyo, GlaxoSmithKline, Reliant, Merck & Company, Merck/Schering-Plough, and Schering-Plough; and served as a consultant and advisor for Abbott, GlaxoSmithKline, Metabolex, San Jose, California, Reliant, Takeda, AstraZeneca, and Essentialis, Carlsbad, California. Dr. Leiter received grants and speakers' honoraria from and served as a consultant and advisor for AstraZeneca, Merck & Company, Merck/Schering-Plough, and Pfizer, New York, New York. Mr. Bird, Mr. Rubino, and Drs. Lowe, Tomassini, and Tershakovec are employees of Merck & Company and may own stock and/or hold stock options in the company.. The American Journal of Cardiology. 102(11). 1489–1494. 62 indexed citations
7.
Pearson, Thomas A., Christie M. Ballantyne, Enrico P. Veltri, et al.. (2008). Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy. The American Journal of Cardiology. 103(3). 369–374. 73 indexed citations
8.
Leiter, Lawrence A., Harold Bays, Scott Conard, et al.. (2008). Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease. The American Journal of Cardiology. 102(11). 1495–1501. 71 indexed citations
9.
Desjardins, Paul J., Peter M. Black, Stephen E. Daniels, et al.. (2007). A Double-Blind Randomized Controlled Trial of Rofecoxib and Multidose Oxycodone/Acetaminophen in Dental Impaction Pain. Journal of Oral and Maxillofacial Surgery. 65(8). 1624–1632. 12 indexed citations
10.
Secombes, Christopher J., Steven Bird, & Jun Zou. (2005). Adaptive immunity in teleosts: cellular immunity.. Developmental Biology. 121. 25–32. 1 indexed citations
11.
Zeiger, Robert S., Steven Bird, Michael Kaplan, et al.. (2005). Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. The American Journal of Medicine. 118(6). 649–657. 46 indexed citations
12.
Chang, David J., Paul J. Desjardins, Steven Bird, et al.. (2004). Comparison of rofecoxib and a multidose oxycodone/acetaminophen regimen for the treatment of acute pain following oral surgery: a randomized controlled trial. Current Medical Research and Opinion. 20(6). 939–949. 25 indexed citations
13.
Desjardins, Paul J., Peter M. Black, Steven Bird, et al.. (2004). A randomized controlled study comparing rofecoxib, diclofenac sodium, and placebo in post-bunionectomy pain. Current Medical Research and Opinion. 20(10). 1523–1537. 30 indexed citations
14.
Ilowite, Jonathan, R. Clinton Webb, Bruce Friedman, et al.. (2004). Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study. Annals of Allergy Asthma & Immunology. 92(6). 641–648. 52 indexed citations
15.
Storms, William W., et al.. (2004). A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respiratory Medicine. 98(11). 1051–1062. 69 indexed citations
16.
17.
Israel, Elliot, Paul Chervinsky, Bruce Friedman, et al.. (2002). Effects of montelukast and beclomethasone on airway function and asthma control. Journal of Allergy and Clinical Immunology. 110(6). 847–854. 90 indexed citations
18.
19.
20.
West, David J., et al.. (1997). Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. The Pediatric Infectious Disease Journal. 16(6). 593–599. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eyal Leibovitz Breakdown of academic impact, for papers by Carlos Alves Breakdown of academic impact, for papers by Florence N. Hutchison Breakdown of academic impact, for papers by Dong‐Soo Kim Breakdown of academic impact, for papers by Haralambos Milionis Breakdown of academic impact, for papers by Ming‐Yow Hung Breakdown of academic impact, for papers by Stanislav Šuškovič Breakdown of academic impact, for papers by P. J. Brombacher Breakdown of academic impact, for papers by Jetty A. Overbeek Breakdown of academic impact, for papers by C G Wathen
Rankless by CCL
2026